SWOT Analysis

Strength: Wide range of drugs available for treatment of pulmonary diseases. Growing awareness regarding respiratory illnesses.
Weakness: High costs associated with development of novel treatment regimens. Side effects of few drugs discourage compliance.
Opportunity: Rising pollution and urbanization in developing nations present an opportunity. Untapped rural markets yet to adopt pulmonary drugs.
Threats: Patent expiry of blockbuster drugs. Slow regulatory approval process delays market entry.

Key Takeaways

Global Pulmonary Drugs Market Size is expected to witness high growth, exhibiting CAGR of 8.1% over the forecast period, due to increasing prevalence of respiratory diseases across both developed and developing nations.

The regional analysis indicates that North America dominated the market in 2023, owing to growing elderly population, favorable reimbursement policies, and strong presence of key players in the region. However, Asia Pacific is anticipated to witness fastest growth during the forecast period due to rising pollution levels, growing healthcare expenditure, and favourable government support.

Key players operating in the pulmonary drugs market are Sanofi SA, Meda Pharmaceuticals, Circassia Pharmaceuticals Plc., AstraZenca Plc., GlaxoSmithKline Plc., Mallinckrodt Pharmaceuticals Plc., Cheisi farmaceutici S.p.A., Zambon Company S.p.A., Alaxia SAS, and Merck Sharp & Dohme Limited. The market is highly competitive with these players introducing generic versions for drugs losing patents and focusing on development of innovative delivery systems. 

Read More- https://www.zupyak.com/p/3906390/t/increasing-prevalence-of-copd-to-drive-growth-of-the-pulmonary-drugs-market